We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease

By LabMedica International staff writers
Posted on 26 Jun 2026

Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. More...

In primary Sjögren disease, inflammation of salivary and lacrimal glands leads to dry mouth and dry eyes alongside systemic complications, underscoring an unmet need for disease-modifying strategies. CD4+ T cells are key orchestrators, but contributions from tissue-resident cells remain poorly defined. A new study reveals a disease-driving interaction between immune cells and fibroblasts in primary Sjögren disease.

Researchers at Tokushima University (Tokushima, Japan) describe a pathogenic axis between CD153+ CD4+ T cells and CD30+ fibroblasts in primary Sjögren disease (pSjD). The work identifies nonimmune fibroblasts, the structural cells that form tissue architecture, as active contributors to disease propagation rather than passive bystanders. The authors present this immune–stromal crosstalk as a central driver of glandular inflammation.

Using a mouse model of pSjD, the team performed high-resolution single-cell RNA sequencing and T cell receptor sequencing of salivary gland cells to map cellular interactions. The analysis showed that CD153+ CD4+ T cells directly engage CD30+ fibroblasts, triggering fibroblast activation, proliferation, and secretion of inflammatory chemokines. These signals recruit additional immune cells and sustain tertiary lymphoid structure–like tissues within the glands, creating a self-reinforcing pathogenic microenvironment.

Functional experiments further supported the role of this pathway. Removing CD153 from CD4+ T cells or neutralizing fibroblast-derived chemokines reduced immune-cell infiltration and significantly halted autoimmune-like pathology in the mouse model. Analyses of patient samples similarly showed increased CD153+ CD4+ T cells and CD30+ fibroblasts that preferentially interact, with CD153–CD30 axis activity positively correlating with disease severity. The expansion of these cells in affected tissues may therefore serve as a novel biomarker for diagnosis and/or monitoring of disease progression.

The findings were published in Nature Communications. Participating institutions include the Department of Immunology and Parasitology, Graduate School of Medicine, Tokushima University, and the Department of Oral and Maxillofacial Surgery, Tokushima University Hospital. 

“Our study provides a new perspective on autoimmune diseases and demonstrates that chronic inflammation is maintained not only by abnormal immune cells but also through interactions between immune cells and tissue-resident fibroblasts,” said Kunihiro Otsuka, Assistant Professor, Department of Oral and Maxillofacial Surgery, Tokushima University Hospital, Japan.

“Importantly, it highlights that fibroblasts create a pathological microenvironment that worsens the diseased condition through direct interaction with abnormal immune cells. This concept has significant implications in therapeutics for rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and chronic inflammatory disorders associated with fibrosis,” added Otsuka.

Related Links
Tokushima University


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.